Scoggin Management’s Immunovant IMVT Stock Holding History

Scoggin Management’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-250,000	Closed	-$2.45M	–	74
2019 Q2	$2.45M	Buy	+250,000	New	+$2.47M	0.63%	34

Other funds holding IMVT

Governors Lane New York $1.56B AUM 30.42% 1-Year Est. Return

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Walleye Trading

Walleye Trading New York $60B AUM 42.19% 1-Year Est. Return

HGC Investment Management Toronto, Ontario, Canada $451M AUM 8.78% 1-Year Est. Return

K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

Scoggin Management's IMVT Position: Q3 2019 in Review

Scoggin Management sold out of Immunovant (IMVT) in Q3 2019, closing a stake of 250,000 shares — an estimated $2.45M sold.

Scoggin Management first reported a position in IMVT in Q2 2019 and held it in 1 quarter. The position peaked at $2.45M in Q2 2019. 14 funds tracked by Wall St. Rank hold IMVT as of Q3 2019.

Scoggin Management reported no remaining Immunovant position as of Q3 2019 after selling out during the quarter.
Scoggin Management sold 250,000 Immunovant shares in Q3 2019, an estimated $2.45M.
Scoggin Management first reported a position in Immunovant in Q2 2019 and held it in 1 quarter.
Scoggin Management's Immunovant position peaked at $2.45M in Q2 2019.
14 funds tracked by Wall St. Rank held Immunovant as of Q3 2019.

Based on Scoggin Management's 13F filing for Q3 2019, filed 14 Nov 2019.